GSK plc (NYSE:GSK) Position Lowered by Virtu Financial LLC

Virtu Financial LLC decreased its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 43.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,542 shares of the pharmaceutical company's stock after selling 22,958 shares during the period. Virtu Financial LLC's holdings in GSK were worth $1,208,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Second Line Capital LLC purchased a new position in shares of GSK in the 3rd quarter valued at about $245,000. Rehmann Capital Advisory Group increased its holdings in GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock valued at $232,000 after buying an additional 332 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of GSK by 36.9% during the 3rd quarter. TD Private Client Wealth LLC now owns 12,422 shares of the pharmaceutical company's stock valued at $508,000 after acquiring an additional 3,346 shares during the period. Sunbelt Securities Inc. boosted its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Finally, Continuum Advisory LLC grew its holdings in shares of GSK by 4.8% in the 3rd quarter. Continuum Advisory LLC now owns 10,599 shares of the pharmaceutical company's stock worth $433,000 after acquiring an additional 487 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Finally, Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, GSK presently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Trading Down 0.6 %

Shares of GSK stock traded down $0.22 during trading hours on Friday, reaching $33.95. The stock had a trading volume of 3,391,380 shares, compared to its average volume of 4,159,023. The firm has a market capitalization of $70.36 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 1.54 and a beta of 0.64. GSK plc has a 1 year low of $32.83 and a 1 year high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm has a 50 day simple moving average of $36.18 and a two-hundred day simple moving average of $39.28.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a $0.3928 dividend. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.63%. The ex-dividend date is Friday, November 15th. GSK's dividend payout ratio is currently 99.35%.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the company's stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company's stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.